Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Blueprint of Collapse: Precision Biomarkers, Molecular Cascades, and the Engineered Decline of Fast-Progressing ALS

21 Aug 2025

Abstract excerpt

Amyotrophic lateral sclerosis (ALS) is still a heterogeneous neurodegenerative disorder that can be identified clinically and biologically, without a strong set of biomarkers that can adequately measure its fast rate of progression and molecular heterogeneity. In this review, we intend to consolidate the most relevant and timely advances in ALS biomarker discovery, in order to begin to bring molecular, imaging,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyotrophic Lateral Sclerosis Research
Share to Neurogenetic and Muscular Disorders Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40869392
DOI: 10.3390/ijms26168072

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Blueprint of Collapse: Precision Biomarkers, Molecular Cascades, and the Engineered Decline of Fast-Progressing ALSPMID 40869392Read ↗

Emerging biomarkers in amyotrophic lateral sclerosis: from pathogenesis to clinical applicationsSemantic proximity Read ↗

Perspectives in Amyotrophic Lateral Sclerosis: Biomarkers, Omics, and Gene Therapy Informing Disease and TreatmentSemantic proximity Read ↗

From phenotype to biology: a multi-modal roadmap of biofluid, tissue, imaging, and digital biomarkers in Parkinson's disease.Semantic proximity Read ↗

The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology.Semantic proximity Read ↗

Studies of Genetic and Proteomic Risk Factors of Amyotrophic Lateral Sclerosis Inspire Biomarker Development and Gene TherapySemantic proximity Read ↗

Unraveling the multifaceted insights into amyotrophic lateral sclerosis: Genetic underpinnings, pathogenesis, and therapeutic horizons.Semantic proximity Read ↗

Current Understanding of ALS Onset, Progression and TreatmentsSemantic proximity Read ↗

Amyotrophic Lateral Sclerosis: New Insights into Underlying Molecular Mechanisms and Opportunities for Therapeutic InterventionSemantic proximity Read ↗

Skeletal muscle biomarkers of amyotrophic lateral sclerosis: a large-scale, multi-cohort proteomic studySemantic proximity Read ↗

The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseasesSemantic proximity Read ↗

Analysis of circulating protein aggregates reveals pathological hallmarks of amyotrophic lateral sclerosisSemantic proximity Read ↗

Biomarkers in Motor Neuron Disease: A State of the Art ReviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.